Compare SAMG & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | PMVP |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.5M | 76.8M |
| IPO Year | 2012 | 2020 |
| Metric | SAMG | PMVP |
|---|---|---|
| Price | $10.79 | $1.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.2K | ★ 272.5K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $91,358,000.00 | N/A |
| Revenue This Year | $8.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $363.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.68 | $0.96 |
| 52 Week High | $16.97 | $1.88 |
| Indicator | SAMG | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 32.03 | 34.35 |
| Support Level | $10.68 | $1.04 |
| Resistance Level | $11.66 | $1.26 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 26.79 | 14.00 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income, and cash, as well as non-traditional investment strategies including hedge funds, private equity funds, real estate, and commodities. The firm offers a full suite of complementary and customized family office services for families seeking comprehensive oversight of their financial affairs. The company derives revenues from Managed accounts, Silvercrest funds, Tax and family office services, and Fund administration. The firm generates the majority of its revenue from Managed Accounts.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.